CDI is the most common cause of healthcare-associated infectious diarrhea, with an estimated 462,000 cases annually in the United States. [1-2] The following is a comprehensive clinical summary organized for emergency medicine and primary care workflows.
1. History
- Key HPI: Onset, frequency, and character of diarrhea (watery, non-bloody); ≥3 unformed stools in 24 hours is the threshold for testing [1][3]
- Antibiotic exposure: Within the past 3 months — the single strongest risk factor. Duration, number, and type of antibiotics (highest risk: clindamycin, fluoroquinolones, cephalosporins, carbapenems) [2][4]
- Healthcare contact: Recent hospitalization, long-term care facility stay, outpatient procedures, or ED visits [1-2]
- Timing: Symptoms typically manifest during or shortly after antibiotic therapy but can be delayed up to 3 months after discontinuation [2]
- Associated symptoms: Abdominal cramping/pain, fever, nausea, anorexia, malaise
- Important negatives: Bloody stool (uncommon in CDI — consider alternative diagnoses), alternating constipation (suggests post-infectious IBS or colonization rather than active CDI), laxative use (exclude before testing) [1]
2. Alarm Features
- WBC ≥15,000/µL or serum creatinine ≥1.5× baseline → severe CDI [1-2]
- Hypotension, shock, ileus, toxic megacolon, or organ failure → fulminant CDI [2]
- WBC ≥35,000 or <4,000, lactate ≥5 mmol/L, bandemia ≥10% → predictors of mortality [5]
- Absence of diarrhea with abdominal distension (ileus) — may signal progression to fulminant disease [2]
- Peritoneal signs, pneumoperitoneum, or pneumatosis on imaging → surgical emergency [2]
3. Medications
- Causative agents (highest risk): Clindamycin, fluoroquinolones, 3rd-generation cephalosporins, carbapenems, ampicillin/amoxicillin-clavulanate [2][4]
- Proton pump inhibitors: Associated with increased CDI risk and recurrence [6-7]
- First-line treatment:
- Fidaxomicin 200 mg PO BID × 10 days (preferred — lower recurrence vs vancomycin) [4][8]
- Oral vancomycin 125 mg PO QID × 10 days (acceptable alternative) [4]
- Metronidazole is no longer recommended as first-line in adults; reserved only when vancomycin and fidaxomicin are unavailable [9-10]
- Fulminant CDI: Oral vancomycin 500 mg QID + IV metronidazole 500 mg Q8H ± rectal vancomycin (500 mg in 100 mL NS retention enema Q6H) if ileus present [2][11]
- Bezlotoxumab (anti-toxin B monoclonal antibody): Adjunct to reduce recurrence in high-risk patients; note current supply shortage [12-13]
- Contraindicated: Do not use anti-motility agents (loperamide) in moderate-severe CDI — risk of toxic megacolon
4. Diet
- Aggressive oral rehydration or IV fluids for volume depletion
- No specific dietary triggers; maintain adequate nutrition — malnutrition is a risk factor for CDI [2]
- Avoid unnecessary bowel rest; enteral nutrition is preferred when tolerated
- Probiotics are not recommended by IDSA for CDI prevention [9]
5. Review of Systems
- GI: Stool frequency/consistency, blood in stool, abdominal pain/distension, nausea/vomiting, obstipation (ileus)
- Constitutional: Fever, chills, malaise, weight loss
- Renal: Decreased urine output (AKI from dehydration or severe sepsis)
- Neurologic: Altered mental status (sepsis marker)
- Cardiopulmonary: Tachycardia, hypotension, dyspnea (sepsis/shock)
6. Collateral History and Family History
- Confirm recent antibiotic prescriptions (including outpatient courses)
- Recent hospitalizations, nursing home stays, or contact with known CDI patients
- Household contacts with CDI (community-acquired transmission)
- Family history is generally not contributory; CDI is not a hereditary condition
- Social context: Residence in long-term care facility significantly increases risk [1]
7. Risk Factors
- Antibiotic use within 3 months (strongest modifiable risk factor) [2][4]
- Age ≥65 years [1][7]
- Healthcare facility exposure (inpatient, outpatient, long-term care) [1]
- Immunosuppression: Chemotherapy, organ transplant, corticosteroids, HIV [2][6]
- Comorbidities: IBD (especially ulcerative colitis), CKD, CHF, diabetes, liver disease [2]
- PPI use (especially if started during or after CDI) [7]
- GI surgery, tube feeding, bowel preparation [2]
- Prior CDI episode — recurrence risk increases with each episode (20% after first, up to 60% after third) [14]
8. Differential Diagnosis
- Antibiotic-associated diarrhea (non-CDI) — accounts for ~70% of antibiotic-associated diarrhea [2]
- Inflammatory bowel disease flare (Crohn's, UC) — can coexist with CDI
- Ischemic colitis — especially in elderly with vascular risk factors
- Infectious colitis: Salmonella, Shigella, Campylobacter, CMV (immunocompromised)
- Post-infectious IBS — occurs in up to 25% of patients after CDI; diarrhea-predominant, alternating patterns [1]
- Medication-related diarrhea (metformin, colchicine, SSRIs, magnesium-containing antacids)
- Small bowel bacterial overgrowth (SIBO)
- Microscopic colitis — chronic watery diarrhea, normal endoscopy
9. Past Medical History
- Prior CDI episodes (number, timing, treatments used) — critical for guiding therapy [1]
- IBD history (increases CDI risk and complicates diagnosis) [2]
- Immunosuppressive conditions or medications
- Recent surgeries (especially GI) [2]
- Chronic kidney disease, liver disease, diabetes [2]
- History of FMT or microbiota-based therapy
10. Physical Exam
- Vital signs: Fever (>38.5°C in ~1% of severe CDI), tachycardia, hypotension [1]
- Abdomen: Diffuse tenderness, distension, decreased bowel sounds (ileus), rebound/guarding (peritonitis — surgical emergency) [2]
- Volume status: Dry mucous membranes, poor skin turgor, delayed capillary refill
- Rectal exam: Watery stool, no gross blood (bloody stool suggests alternative diagnosis)
- Physical exam alone has limited diagnostic utility for CDI — no clinical finding reliably increases likelihood [15]
11. Lab Studies
- Do not test formed stool — high false-positive rate from colonization [3]
- Do not repeat testing within 7 days if NAAT negative; do not perform "test of cure" [3]
12. Imaging
- Not routinely indicated for nonsevere CDI [2]
- CT abdomen/pelvis with IV contrast: Indicated for suspected severe/fulminant disease or peritonitis
- Findings: Colonic wall thickening (most common, but nonspecific), "accordion sign" (oral contrast trapped between edematous haustral folds), "double-halo/target sign", pericolonic fat stranding, ascites [2][16-17]
- ~40% of CDI patients have a normal CT [2]
- CT sensitivity for CDI is only 52–85% [2]
- Abdominal X-ray: May show dilated colon (toxic megacolon >6 cm), thumbprinting, or free air [16-17]
- Point-of-care ultrasound: Useful in critically ill patients who cannot be transported; may show thickened colonic wall and free fluid [18]
13. Special Tests
The ATLAS score is a validated bedside scoring system for predicting treatment response in CDI, incorporating age, treatment with systemic antibiotics, leukocyte count, albumin, and creatinine. [18]
- Flexible sigmoidoscopy: Reserved for high clinical suspicion with negative stool testing; may reveal pathognomonic pseudomembranes (yellow-white plaques), though present in only ~45–55% of confirmed CDI [2][18]
- Rectal swab PCR: Acceptable alternative when patients with ileus cannot produce stool [1][18]
- Stool leukocytes: LR+ 5.31 for CDI — one of the few clinical features that meaningfully increases likelihood [15]
14. ECG
- No CDI-specific ECG findings
- ECG indicated in the setting of sepsis/shock to evaluate for tachyarrhythmias, ischemia, or electrolyte-related changes (hypokalemia, hypomagnesemia from severe diarrhea)
- Monitor for QTc prolongation if using IV metronidazole or if concurrent electrolyte derangements
15. Assessment
Severity stratification (per IDSA/SHEA 2021): [1-2][8]
- Recurrence occurs in ~20% after initial episode and up to 60% after ≥3 episodes [14]
- Atypical presentations: Ileus without diarrhea, isolated leukocytosis, small bowel involvement (rare, mainly in patients with ileostomy) [2]
- Complications: Toxic megacolon, colonic perforation, septic shock, AKI, death (mortality up to 14% in severe CDI) [2]
16. Treatment Plan
The following figure summarizes the management algorithm for initial and recurrent CDI:
Initial nonsevere CDI
- Fidaxomicin 200 mg PO BID × 10 days (preferred) OR oral vancomycin 125 mg QID × 10 days [4][8]
- Discontinue the inciting antibiotic if possible [9]
Severe CDI
Fulminant CDI
- Oral vancomycin 500 mg QID + IV metronidazole 500 mg Q8H [2][11]
- If ileus: Add rectal vancomycin retention enemas (500 mg in 100 mL NS Q6H) [2]
- Early surgical consultation — do not delay [2]
- Consider FMT after 48–72 hours of failed maximal medical therapy as bridge to or alternative to surgery [1]
Surgical options for fulminant/refractory CDI
- Total abdominal colectomy with end ileostomy remains the standard of care (mortality 31–57%) [1-2]
- Diverting loop ileostomy (DLI) with antegrade colonic vancomycin lavage is an emerging colon-preserving alternative with comparable mortality and significantly higher ostomy reversal rates (80% vs 25%) [2][20-21]
Recurrent CDI
- First recurrence: Fidaxomicin (standard or extended-pulsed) or vancomycin taper/pulse [1][4][8]
- Second or subsequent recurrence: Antibiotic course followed by fecal microbiota transplant (FMT) or FDA-approved live biotherapeutic products (fecal microbiota live-jslm [Rebyota], fecal microbiota spores live-brpk [Vowst]) [4][14][22]
- Bezlotoxumab as adjunct to reduce recurrence in high-risk patients [10][13]
17. Disposition
- Discharge criteria (nonsevere CDI): Tolerating oral medications, adequate hydration, stable vitals, reliable follow-up, no signs of severe disease
- Admission criteria: Severe or fulminant CDI, inability to tolerate oral medications, significant dehydration, hemodynamic instability, WBC >15,000, elevated creatinine, elderly/frail patients without adequate home support [2]
- ICU admission: Fulminant CDI with shock, organ failure, ileus, or toxic megacolon [2]
- Surgical consultation triggers: Fulminant disease, peritoneal signs, toxic megacolon, failure to improve after 48–72 hours of maximal medical therapy, perforation [2][23]
- Infection control: Implement contact precautions immediately; hand hygiene with soap and water (alcohol-based sanitizers do not kill spores) during outbreaks [9]
18. Follow Up / Return Precautions
- Follow-up: Primary care within 1–2 weeks of discharge; GI referral for recurrent CDI
- Expected course: Diarrhea typically improves within 3–5 days of treatment; complete resolution may take up to 2 weeks [24]
- Do not perform test of cure — shedding persists in 56% of patients up to 4 weeks after successful treatment [1]
- Recurrence window: Most recurrences occur within 8 weeks of completing treatment [1]
- Return precautions — seek immediate care for:
- Worsening or recurrent diarrhea (≥3 watery stools/day)
- Fever, severe abdominal pain or distension
- Bloody stool, inability to keep fluids down
- Lightheadedness, decreased urine output
- Patient counseling: Complete the full antibiotic course; avoid unnecessary future antibiotic use; discuss PPI deprescribing if appropriate; post-infectious IBS-like symptoms may persist for months [1][4]
References
1. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides Difficile Infections. — Kelly CR, Fischer M, Allegretti JR, et al. The American Journal of Gastroenterology. 2021.
2. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides Difficile Infection. — Poylin V, Hawkins AT, Bhama AR, et al. Diseases of the Colon and Rectum. 2021.
3. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
4. Recurrent Clostridioides difficile Infections. — van Prehn J, Kuijper EJ, Dubberke ER. The Journal of the American Medical Association. 2025.
5. Acute Abdomen in the Immunocompromised Patient: WSES, SIS-E, WSIS, AAST, and GAIS Guidelines. — Coccolini F, Improta M, Sartelli M, et al. World Journal of Emergency Surgery : WJES. 2021.
6. Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridioides Difficile (Clostridium Difficile). — Minkoff NZ, Aslam S, Medina M, et al. The Cochrane Database of Systematic Reviews. 2023.
7. Prognostic Factors for Severe and Recurrent Clostridioides Difficile Infection: A Systematic Review. — van Rossen TM, Ooijevaar RE, Vandenbroucke-Grauls CMJE, et al. Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2022.
8. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides Difficile Infection in Adults. — Johnson S, Lavergne V, Skinner AM, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2021.
9. Clostridioides Difficile Infection: Update on Management. — Mounsey A, Lacy Smith K, Reddy VC, Nickolich S. American Family Physician. 2020.
10. European Society of Clinical Microbiology and Infectious Diseases: 2021 Update on the Treatment Guidance Document for Clostridioides Difficile Infection in Adults. — van Prehn J, Reigadas E, Vogelzang EH, et al. Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2021.
11. Management of Clostridioides Difficile Infection in Adults and Challenges in Clinical Practice: Review and Comparison of Current IDSA/SHEA, ESCMID and ASID Guidelines. — Bishop EJ, Tiruvoipati R. The Journal of Antimicrobial Chemotherapy. 2022.
12. FDA Orange Book. — FDA Orange Book. 2026.
13. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. — Constance Benson, John Brooks, Shireesha Dhanireddy, et al Infectious Diseases Society of America; Office of AIDS Research Advisory Council (2025). 2025.
14. Recurrent Clostridioides Difficile Infection: Current Clinical Management and Microbiome-Based Therapies. — Berry P, Khanna S. BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 2023.
15. Does This Patient Have Clostridioides Difficile Infection? A Systematic Review and Meta-Analysis. — Manzoor F, Manzoor S, Pinto R, et al. Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2023.
16. Gastrointestinal Surgical Emergencies Textbook. — Ashley E. Aaron, Andrea Amabile, Ciro Andolfi, et al American College of Surgeons (2021). 2021.
17. Pseudomembranous Colitis: Spectrum of Imaging Findings With Clinical and Pathologic Correlation. — Kawamoto S, Horton KM, Fishman EK. Radiographics : A Review Publication of the Radiological Society of North America, Inc. 1999.
18. 2019 Update of the WSES Guidelines for Management of Clostridioides (Clostridium) Difficile Infection in Surgical Patients. — Sartelli M, Di Bella S, McFarland LV, et al. World Journal of Emergency Surgery : WJES. 2019.
19. Review article: The epidemiology and management of Clostridioides difficile infection—A clinical update. — Clarke LM, Allegretti JR. Alimentary Pharmacology & Therapeutics. 2024.
20. Diverting Loop Ileostomy With Antegrade Colonic Lavage Compared With Colectomy in Clostridioides Difficile Colitis: A Decade-Long Propensity Score-Matched Analysis. — Zangbar B, Mehta R, Kirsch J, et al. The Journal of Trauma and Acute Care Surgery. 2026.
21. Total Abdominal Colectomy Versus Diverting Loop Ileostomy With Colonic Lavage for Fulminant Clostridium Difficile Colitis: An Updated Systematic Review and Meta-Analysis of Outcomes. — Aljaafreh A, Hojeij M, Ataya K, et al. Langenbeck's Archives of Surgery. 2024.
22. Diagnosis and Management of Clostridioides Difficile. — Kelly CR, Feuerstadt P. The American Journal of Gastroenterology. 2026.
23. Management of Severe Clostridioides Difficile Infection. — Salrin J, Stewart DB. Infectious Disease Clinics of North America. 2025.
24. My Treatment Approach to Clostridioides Difficile Infection. — Khanna S. Mayo Clinic Proceedings. 2021.